Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 62 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		A Phase III Study of Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase CML

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				CA180-056 NCT00481247


2.		Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				CA180-227 NCT00744497

Last Modified: 10/23/2008 First Published: 5/1/2002


3.		Phase II Study of a Non-Myeloablative Conditioning Regimen Comprising Fludarabine and Total Body Irradiation Followed By Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Imatinib Mesylate, Dasatinib, or Nilotinib-Responsive Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia in Blast Crisis

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				70 and under				NCI				FHCRC-1581.00 5235, NCI-H02-0087, NCT00036738


4.		Study of BMS-354825 in Children and Adolescents With Relapsed or Refractory Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				1 to 20				Pharmaceutical / Industry				CA180-018 Protocol ITCC 005, NCT00306202


5.		Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				CA180-086 NCT00439270


6.		Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				19 and over				Other				IRB#244-07-FB BMS Protocol 180129, NCT00550615


7.		Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				Other				2006-0900 NCT00566618


8.		A Phase I/II Study of Dasatinib and Dacarbazine

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				MCC-15256 USFIRB#106128, CA180-092, NCT00597038


9.		A Phase I/Expansion Study of Dasatinib

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				9335 NCT00598091

First Published: 11/6/2008


10.		Phase I/II Study of Dasatinib in Combination With Ifosfamide, Carboplatin, and Etoposide Phosphate in Young Patients With Metastatic or Recurrent Malignant Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				1 to 25				NCI, Pharmaceutical / Industry				CHNMC-07053 07053, CA180 121, NCT00788125

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute